Literature DB >> 28652437

Increased Resistance of Skin Flora to Antimicrobial Prophylaxis in Patients Undergoing Hip Revision Arthroplasty.

Heinrich M L Mühlhofer1, Lukas Deiss2, Philipp Mayer-Kuckuk2, Florian Pohlig2, Norbert Harrasser2, Ulrich Lenze2, Hans Gollwitzer2, Christian Suren2, Peter Prodinger2, Rüdiger VON Eisenhart-Rothe2, Johannes Schauwecker2.   

Abstract

BACKGROUND/AIM: Prosthetic joint infection (PJI) remains a major complication after total joint replacement and is the primary indication for revision arthroplasty. Specifically, coagulase-negative Staphylococci (CNS) can cause low-grade infections. Despite the use of cephalosporin-based antimicrobial prophylaxis (AMP) and antiseptic treatment at the surgical site, evidence suggests that a significant number of cases of dermal CNS results in low-grade PJI. Thus, this study examined the bacterial colonization and resistance patterns at the surgical site. We hypothesized that the bacteria developed resistance to antibiotics that are frequently used in primary and revision total hip arthroplasty (THA) procedures. PATIENTS AND METHODS: Ninety patients, including 63 primary and 27 revision THA patients, were enrolled in this study. For each patient, a single swab of the skin at the surgical site was subjected to clinical microbiology to assess bacterial colonization. Furthermore, resistance to a sentinel panel of antibiotics (benzylpenicillin, erythromycin, tetracycline, oxacillin, fusidic acid, clindamycin, gentamicin, levofloxacin/moxifloxacin, rifampicin, linezolid and vancomycin) was tested.
RESULTS: In 96.7% of the patients, at least one bacterial strain was identified at the surgical site, with CNS strains comprising 93.1% of the total. The sentinel panel showed that 30.7% of the CNS strains exhibited maximal resistance to oxacillin, a commonly used cephalosporin. Additionally, oxacillin resistance increased 1.9-fold (p=0.042) between primary and revision THA. Notably, 8.1% of the CNS stains found on patients undergoing primary THA were resistant to gentamicin, an aminoglycoside, and this rate increased 4.7-fold (p=0.001) for patients undergoing revision THA.
CONCLUSION: CNS strains have significant resistance to standard AMP, particularly in individuals undergoing revision THA. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Prosthetic joint infection; antimicrobial prophylaxis; coagulase-negative Staphylococci

Mesh:

Substances:

Year:  2017        PMID: 28652437      PMCID: PMC5566920          DOI: 10.21873/invivo.11111

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  26 in total

Review 1.  Prevention of perioperative infection.

Authors:  Nicholas Fletcher; D'Mitri Sofianos; Marschall Brantling Berkes; William T Obremskey
Journal:  J Bone Joint Surg Am       Date:  2007-07       Impact factor: 5.284

Review 2.  Incidence and risk factors for deep surgical site infection after primary total hip arthroplasty: a systematic review.

Authors:  Donna M Urquhart; Fahad S Hanna; Sharon L Brennan; Anita E Wluka; Karin Leder; Peter A Cameron; Stephen E Graves; Flavia M Cicuttini
Journal:  J Arthroplasty       Date:  2009-10-30       Impact factor: 4.757

Review 3.  Guideline for use of topical antimicrobial agents.

Authors:  E Larson
Journal:  Am J Infect Control       Date:  1988-12       Impact factor: 2.918

4.  Long-term results of prophylactic cefazolin versus placebo in total hip replacement.

Authors:  F Doyon; J Evrard; F Mazas; C Hill
Journal:  Lancet       Date:  1987-04-11       Impact factor: 79.321

Review 5.  Current concepts for clean air and total joint arthroplasty: laminar airflow and ultraviolet radiation: a systematic review.

Authors:  Richard P Evans
Journal:  Clin Orthop Relat Res       Date:  2011-04       Impact factor: 4.176

6.  Differences in the risk factors for surgical site infection between total hip arthroplasty and total knee arthroplasty in the Korean Nosocomial Infections Surveillance System (KONIS).

Authors:  Kyoung-Ho Song; Eu Suk Kim; Young Keun Kim; Hye Young Jin; Sun Young Jeong; Yee Gyung Kwak; Yong Kyun Cho; Joohon Sung; Yeong-Seon Lee; Hee-Bok Oh; Tae Kyun Kim; Kyung-Hoi Koo; Eui-Chong Kim; June Myung Kim; Tae Yeol Choi; Hyo Youl Kim; Hee Jung Choi; Hong Bin Kim
Journal:  Infect Control Hosp Epidemiol       Date:  2012-09-24       Impact factor: 3.254

7.  Antibiotic resistance profiles of coagulase-negative staphylococci in livestock environments.

Authors:  Sonja M K Schoenfelder; Ying Dong; Andrea T Feßler; Stefan Schwarz; Christoph Schoen; Robin Köck; Wilma Ziebuhr
Journal:  Vet Microbiol       Date:  2016-04-30       Impact factor: 3.293

8.  Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register.

Authors:  Lars B Engesaeter; Stein Atle Lie; Birgitte Espehaug; Ove Furnes; Stein Emil Vollset; Leif Ivar Havelin
Journal:  Acta Orthop Scand       Date:  2003-12

Review 9.  Prophylactic antibiotics in hip and knee arthroplasty.

Authors:  John Meehan; Amir A Jamali; Hien Nguyen
Journal:  J Bone Joint Surg Am       Date:  2009-10       Impact factor: 5.284

Review 10.  Prosthetic joint infection.

Authors:  Aaron J Tande; Robin Patel
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

View more
  2 in total

1.  Methicillin-Resistant Staphylococcus epidermidis Lineages in the Nasal and Skin Microbiota of Patients Planned for Arthroplasty Surgery.

Authors:  Emeli Månsson; Staffan Tevell; Åsa Nilsdotter-Augustinsson; Thor Bech Johannesen; Martin Sundqvist; Marc Stegger; Bo Söderquist
Journal:  Microorganisms       Date:  2021-01-28

2.  Two-stage revision arthroplasty for coagulase-negative staphylococcal periprosthetic joint infection of the hip and knee.

Authors:  Ewout S Veltman; Dirk Jan F Moojen; Marc L van Ogtrop; Rudolf W Poolman
Journal:  World J Orthop       Date:  2019-10-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.